Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
Allergan Aesthetics (NYSE: ABBV), an AbbVie company, reported that the U.S. FDA has accepted for review a supplemental Biologics License Application for BOTOX® Cosmetic (onabotulinumtoxinA) to treat marked to very marked masseter muscle prominence (MMP) in adults.
If approved, BOTOX Cosmetic would become the first and only neurotoxin indicated for MMP in the U.S. and its fifth aesthetic indication. The sBLA is supported by two Phase 3 studies (M21-416 and M21-417), which met their primary endpoints, showing statistically significant improvements in masseter muscle prominence versus placebo (p=0.0046 and p=0.0014). Safety was consistent with established uses, with no new safety signals, and twice as many treated patients reported being “Very Satisfied” or “Satisfied” compared with placebo. The release also reiterates the existing boxed warning on distant spread of toxin effect, contraindications, key adverse reactions, and other important safety information for BOTOX Cosmetic.
AbbVie (NYSE:ABBV) reported second-quarter 2026 net revenues of $16.99 billion, up 10.2% reported (9.5% operational). GAAP diluted EPS rose 290.4% to $2.03, while adjusted diluted EPS increased 22.9% to $3.65, including a $0.17 per-share unfavorable impact from acquired IPR&D and milestones expense.
Immunology revenues were $8.786 billion (+15.1%), led by Skyrizi at $5.505 billion and Rinvoq at $2.525 billion, while Humira declined to $756 million. Neuroscience revenues reached $3.228 billion (+20.3%), oncology $1.650 billion (-1.5%), and aesthetics $1.282 billion (+0.3% reported, -0.9% operational).
AbbVie announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion in equity value, targeting IL‑13 and TSLP assets, with closing anticipated in third-quarter 2026. Full-year 2026 adjusted EPS guidance was updated from $13.91–$14.11 to $13.87–$14.07, now including an expected $0.14 per-share dilutive impact from the Apogee deal and an unfavorable $0.58 per-share impact from year-to-date acquired IPR&D and milestones expense.
AbbVie (NYSE: ABBV), through its Allergan Aesthetics unit, announced the fourth annual JUVÉDERM® Day will take place in the U.S. on Wednesday, August 19, 2026, coinciding with the 20th anniversary of the brand’s first U.S. FDA dermal filler approval.
Allē, Allergan Aesthetics’ loyalty program with eight million members, will offer U.S. Allē Members a limited-time buy-one-get-one $75 JUVÉDERM® gift card promotion starting 9 a.m. PT/12 p.m. ET on August 19, plus double Allē points on up to two JUVÉDERM® syringes from August 19–31, 2026 (excluding SKINVIVE by JUVÉDERM®), all subject to terms, conditions, and availability.
AbbVie (NYSE: ABBV) announced that the European Commission has approved RINVOQ (upadacitinib) 15 mg once daily for adults and adolescents aged 12 years and older with non-segmental vitiligo (NSV) who are candidates for systemic therapy. With this decision, RINVOQ becomes the first and only systemic medication approved in the European Union for NSV, the most common form of vitiligo.
According to AbbVie, approval is based on the Phase 3 Viti-Up program (M19-044), two replicate randomized, placebo-controlled, double-blind studies in 614 patients, where RINVOQ met co-primary endpoints, achieving statistically significant and clinically meaningful improvements in total body repigmentation (T-VASI 50) and facial repigmentation (F-VASI 75) at week 48 versus placebo, and met ranked secondary endpoints on facial response and disease stabilization, with a safety profile generally consistent with prior indications and no new safety signals.
AbbVie (NYSE: ABBV) announced that the European Commission has approved RINVOQ (upadacitinib) 15 mg and 30 mg once daily for adults and adolescents ≥12 years with severe alopecia areata (AA) in the EU. Approval is based on the pivotal Phase 3 UP‑AA (M23‑716) program, comprising two replicate, randomized, placebo‑controlled, double‑blind studies in 1,399 patients worldwide.
Both doses met the primary endpoint of achieving SALT ≤ 20 at week 24, with significantly more patients reaching ≥80% scalp hair coverage versus placebo, and key secondary endpoints including complete scalp hair regrowth (SALT = 0) and improvements in eyebrows and eyelashes. According to AbbVie, the safety profile in Period A was generally consistent with other approved indications. The EU label also includes extensive safety warnings on serious infections, malignancies, MACE, VTE and use restrictions in higher‑risk populations.
Genmab (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) clarified that in the global Phase 3 EPCORE® DLBCL-1 trial of subcutaneous epcoritamab monotherapy versus investigator’s choice chemoimmunotherapy in adults with relapsed/refractory DLBCL ineligible for autologous stem cell transplant, overall survival (OS) was the sole U.S. primary endpoint and was not met, as the study did not show a statistically significant OS improvement.
The trial remains ongoing with region-specific primary endpoints and further data planned for peer‑reviewed publication. Epcoritamab, co-developed by Genmab and AbbVie, already holds FDA accelerated approval for certain R/R DLBCL and follicular lymphoma indications and is approved in more than 65 territories under the EPKINLY®/TEPKINLY® brands.
Allergan Aesthetics (NYSE: ABBV) announced that the European Commission has approved Boey® (trenibotulinumtoxinE) for the temporary improvement of moderate to severe glabellar lines (frown lines) at maximum frown in adult patients, when these lines have an important psychological impact. The centralized decision applies across all 30 European Economic Area countries.
Boey® is described as the first and only rapid-onset, short-duration botulinum neurotoxin serotype E approved in Europe; in clinical studies, onset of effect was observed as early as eight hours and typically lasted two to three weeks. Boey® also received approval in Canada in June 2026. According to Allergan Aesthetics, the product was developed to offer a differentiated, shorter-acting option for adults considering facial injectables, allowing them to experience treatment results without committing to longer-lasting effects. The company plans a European launch supported by education and training for healthcare professionals. BOTOX® Cosmetic is noted as the only neurotoxin clinically tested for safety following treatment with Boey®.
Allergan Aesthetics (NYSE: ABBV), through its SkinMedica brand, announced an expanded commitment to regenerative science on July 14, 2026. The company launched the SkinMedica Regenerative Science Advisory Board, bringing together physicians, clinicians, and skin health experts to foster scientific dialogue, share clinical best practices, and connect breakthrough research with everyday patient care.
According to Allergan Aesthetics, SkinMedica also expanded its Irvine, California R&D lab to more than double its previous footprint, adding advanced pre-clinical research capabilities, sophisticated imaging, and AI- and machine learning–enabled discovery. In parallel, SkinMedica introduced its first in-practice flagship retail experiences at select U.S. medical aesthetics practices, including locations in Rapid City, South Dakota, and Scottsdale, Arizona, with more sites planned in 2026.
AbbVie (NYSE: ABBV) received European Commission marketing authorization for TEPKINLY (epcoritamab) + lenalidomide + rituximab (R2) to treat adult relapsed or refractory follicular lymphoma in the second-line setting. This fixed‑duration, chemotherapy‑free, bispecific-based regimen is the first of its kind approved in Europe.
In Phase 3 EPCORE FL-1, TEPKINLY + R2 reduced risk of progression or death by 79% (HR 0.21) versus R2, achieved 96% overall response and 74% complete response, versus 81% and 43% for R2. Serious adverse reactions occurred in 44% of patients, including cytokine release syndrome and infections.
AbbVie (NYSE: ABBV) reported positive topline Phase 3 EPCORE DLBCL-4 results for epcoritamab plus lenalidomide in adults with relapsed or refractory diffuse large B-cell lymphoma. The trial met its primary endpoint, showing statistically significant, clinically meaningful improvement in progression-free survival versus R-GemOx, with up to 60% lower risk of progression or death. The chemotherapy-free combination’s safety profile was consistent with the known profiles of epcoritamab and lenalidomide. AbbVie and Genmab plan to discuss next steps with global regulators and submit full data to a future medical meeting.